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MANAGEMENT OF INFRARENAL ABDOMINAL AORTIC ANEURYSM 
BY OPEN REPAIR VERSUS ENDOVASCULAR REPAIR  
 
 
JAMES T. TRUSSLER 
 
ABSTRACT 
 Abdominal aortic aneurysms (AAA) are a pathological dilation of 
the aorta greater than 2.5cm and affect more than 4% of the male 
population and 1% of women aged 60 years or older.  Screening is 
recommended among men and women older than age 65, and is covered 
by Medicare for patients with a family history and men with a history of 
smoking.  Due to its asymptomatic nature, AAA is usually found 
incidentally during another radiological investigation.  Many factors are 
associated with AAA development, but it is most commonly found in 
conjunction with atherosclerosis.  There is currently no pharmacological 
intervention specifically for AAA, though statin therapy has shown some 
promise. 
 The aneurysm will invariably grow, with an average rate of 
expansion of less than 0.5cm per year.  As the aneurysm grows larger 
the chance of the rupture increases significantly with this outcome 
carrying an extremely high rate of mortality.  Surgical intervention is 
recommended once the diameter reaches 5.5cm in men or about 5cm in 
women.  There are two approaches to the repair of the aorta: the open 
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surgical approach and the endovascular approach.  The open surgical 
procedure replaces the affected portion of the aorta with a graft.  The 
endovascular procedure places an endograft within the intact aneurysm, 
effectively excluding the affected section of vessel.  The endovascular 
method carries a lower perioperative mortality rate than the open 
procedure, but over time can require additional surgeries to prevent 
continued aneurysm expansion due to blood flow in the aneurysm sac.  
Additionally, lifetime surveillance of the endograft is required to monitor 
its integrity and effectiveness. 
 Lifestyle changes and possible pharmacological interventions in 
patients with AAA should focus on cardiovascular health changes to 
improve overall health and minimize risk factors for continued 
development of the aneurysm.  In patients who will require repair 
particular attention should be paid to individual risks and preferences.  
The open repair procedure may be preferable in patients with better 
overall health and a longer life expectancy, while endovascular repair 
may be beneficial for more elderly or frail patients.  Research and 
technology in this area are developing quickly, particularly for 
endovascular procedures, and the near future may see important 
changes in the risk-benefit analysis of AAA surgical interventions. 
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I. Introduction 
1. Historical Perspective 
It has been 15 years since the U.S. Food and Drug Administration 
approved in 1999 the first endovascular device for the repair of 
abdominal aortic aneurysms (AAA).  Since then, support for this 
approach has grown, as advances are made in the associated technology 
and its application.  This technology represents a far departure from the 
preferred open surgical treatment of the previous century, and only 
further from the methods described by the Greek surgeon Antyllus in the 
2nd century A.D.  With the advancement of new technologies and 
treatments in medicine and surgery, it is universally prudent to 
understand the appropriate application thereof and the inherent risks 
associated with a novel intervention.  This is particularly true as the 
method and technology continue to progress, and as clinical findings 
influence the way that physicians practice modern medicine. 
 Aneurysms had been recognized early in human medical history, 
with accounts dating back to as early as 1000 B.C. in Egypt (Wilton, 
2012).  During the 2nd century A.D., both Galen and Antyllus set the 
foundations of the modern definition of the aneurysm.  In fact, Antyllus 
performed the earliest recorded attempts to correct AAA when he ligated 
both the proximal and distal necks of the aneurysms via laparotomy.  
Apparently, some small number of his patients was actually able to 
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survive for a period of time following the procedure – a remarkable 
occurrence by today’s standards.  Variations on Antyllus’ procedure for 
ligating the aorta continued into the 20th century, with Rudolf Matas 
performing the first recorded successful aortic ligation, with the patient 
surviving for a significant time following the operation (Matas, 1940).  
Matas also fathered the idea of operating upon the aorta with the intent 
of maintaining blood flow, rather than simply disrupting aneurysm 
formation.  This would go on to become the principal basis for modern 
treatment techniques including open and endovascular aneurysm repair 
(EVAR) (Friedman, 2005). 
 Following work by several surgeons to maintain arterial flow by 
means of bypass and anastomosis, Arthur Voorhees in the mid-20th 
century published the results using a synthetic polyvinyl material to 
bypass the affected portion of an aortic aneurysm (Blakemore & 
Voorhees, 1954).  This work set the stage for the development of the open 
repair technique in the 1950’s.  This became the gold standard of AAA 
treatment for the latter half of the 20th century, with many advances in 
surgery making this a safe and effective procedure.  However, open repair 
is a major invasive procedure and poses a serious risk.  Therefore the 
impetus to develop a less invasive technique to resolve the aneurysm 
bore the endovascular intervention, as an alternative.  In 1991, Juan 
Parodi and colleagues performed the first successful endovascular repair 
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of an aneurysm by a similar technique to that which is used today 
(Parodi, Palmaz, & Barone, 1991).  This milestone would be the 
beginning of the new era of AAA intervention. 
 
2. Epidemiology and Risk 
 AAA affects a significant portion of the population in the U.S., 
particularly the elderly.  It is estimated that 4-8% of men and 
approximately 1% of women over the age of 60 are affected (Baxter, 
Terrin, & Dalman, 2008).  Several studies published in the latter decades 
of the 20th century suggested an increasing incidence of AAA (Melton et 
al., 1984), but some more recent studies are showing a gradual decline 
(Choke et al., 2012; Norman, Spilsbury, & Semmens, 2011; Sandiford, 
Mosquera, & Bramley, 2011) - at least in certain regions of the developed 
world.  There is a distinct possibility that this is due to the changing 
epidemiology of certain major risk factors for AAA. 
 According to the Centers for Disease Control (CDC) fact sheet, AAA 
was the “primary cause of 10,597 deaths and a contributing cause in more 
than 17,215 deaths” in 2009.  Furthermore, it is reported that about 67% 
of aortic ruptures – the natural endpoint of the disease – occur in male 
patients (“Aortic Aneurysm Fact Sheet|Data & Statistics|DHDSP|CDC,” 
n.d.).  Therefore, in 2009, AAA accounted for or contributed to 0.5-0.8% 
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of the over 2,000,000 deaths in the U.S.  This makes AAA the 15th 
leading cause of death in the United States. 
 According to most contemporary studies of AAA, the incidence 
increases with age and the average age of the affected population is 
approximately 70 years (Wilmink & Quick, 1998).  A large multi-centre 
study of screening protocols was conducted over the course of 13 years 
to assess the effect on mortality from AAA in the United Kingdom (Ashton 
et al., 2002; Thompson et al., 2012).  In this study, over 70% of AAAs 
detected on screening were less than 4.5cm in diameter in the study age 
range of 65-74.  This diameter is below that which would typically 
indicate surgical repair, which immediately suggests a benefit to 
screening.  In fact, the MASS study found a consistent 42% risk 
reduction across all 13 years of follow-up, including an incidental benefit 
of 3% reduction in all-cause mortality (Thompson et al., 2012).  The US 
Preventive Services Task Force (USPSTF) recommends a more limited 
screening program due to the associated economic burden.  This 
includes screening amongst men aged 65-75 who have ever smoked and 
among men and women with a family history of AAA.  In fact, since 2007, 
Medicare has paid for a single AAA screening ultrasonography among 
patients fitting the USPSTF guidelines under the Screening Abdominal 
Aortic Aneurysms Very Efficiently (SAAAVE) Act.  Underscoring the 
concerns regarding the costs of screening, however, was an article that 
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reviewed the effect of the SAAAVE Act on AAA screening, repair, and 
mortality, which showed that screening within this program has 
effectively no benefit. (Harris R, Sheridan S, & Kinsinger L, 2012; 
Shreibati J, Baker LC, Hlatky MA, & Mell MW, 2012). 
 One large prospective study conducted by Carlos Iribarren and 
colleagues (2007) investigated a great number of risk factors contributing 
to the presentation of AAA.  The study population was identified between 
1965 and 1971 and follow-up continued until 2003.  Major factors 
identified in this study which are associated with AAA included male 
gender, increasing age, hypertension, and hypercholesterolemia. These 
are typically considered to be the major risk factors for AAA and are also 
strongly associated with atherosclerosis; however there was no predictive 
association between AAA and obesity.  In addition, with the rate of AAA 
amongst smokers being higher to begin with, a dose-dependent 
relationship was identified.  As stated by Iribarren and colleagues, this is 
consistent with prior studies (Pleumeekers et al., 1995; Strachan, 1991).  
A more recent study suggested that diabetes might be a negative 
predictor of aneurysm growth (De Rango et al., 2012). 
 Smoking is one of the most severe risk factors for AAA formation.  
Aneurysm related mortality among smokers carries a hazard ratio of up 
to 6.5 as compared with those who have never smoked (Strachan, 1991).  
This association between AAA and smoking is more significant than the 
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association between cigarettes and cerebrovascular disease or Coronary 
Artery Disease (CAD) (Lederle, Nelson, & Joseph, 2003).  These data 
indicate that smoking could be, as with so many cardiovascular diseases, 
one of the biggest contributing risk factors to AAA development and 
progression. 
 Chronic obstructive pulmonary disease (COPD) may also 
contribute to aortic dilatation.  Macrophage metalloproteinases (MMPs) 
that function as elastases are upregulated in this disease, and the broad 
increase in their expression is a possible contributor to the elastin 
degradation found in the aortic wall of AAA patients (Tetley, 2002).  A 
recent case-control study found an increased prevalence of COPD among 
patients with AAA (Meijer et al., 2012).  The increased prevalence of 
COPD was noted in both smoking and non-smoking AAA patients, 
suggesting that the connection between COPD and AAA is independent of 
cigarette use. 
 Additionally, infectious agents may contribute to aneurysm 
development in some patients.  Cytomegalovirus, Herpesviridae, 
Haemophilus influenzae, and tuberculosis have all been cited as having a 
possible link to AAA formation (Canaud et al., 2008; Sato & Kobayashi, 
2012; Tanaka, Komori, Okadome, Sugimachi, & Mori, 1994).  Despite 
these findings, a direct causal link remains to be seen.  Chlamydiae 
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Pneumoniae has also been implicated in AAA development (Karlsson et 
al., 2000). 
 
3.  Pathophysiology of AAA 
 The normal aorta originates in the left ventricle of the heart and 
gives rise to the right and left coronary arteries, the brachio-cephalic 
artery, the left common carotid, and the left subclavian artery before 
descending.  Known as the thoracic aorta, the artery descends on the left 
side of the spinal column, giving rise to the pericardiac, bronchial, 
esophageal, mediastinal, and intercostal arteries.  The abdominal aorta 
begins as the vessel penetrating the diaphragm.  The first branch to arise 
from this segment is the celiac axis, followed by the superior mesenteric 
and renal arteries.  The region of the aorta between the renal arteries and 
the iliac bifurcation gives rise to the inferior mesenteric artery and the 
lumbar arteries.  This region is the most common site in which AAA is 
found.  Finally, the iliac bifurcation gives rise to the common iliac 
arteries (Gray, 2010). 
 The most commonly recognized trigger for the development of AAA 
is an existing atherosclerosis, however there is only a weak link between 
cause and effect.  Weintraub (2009) describes the following:  “Although 
abdominal aortic aneurysms frequently occur in patients with 
atherosclerosis and the two disease processes share several common risk 
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factors, atherosclerotic lesions are predominantly intimal in location, 
whereas the media and adventitia are primarily involved in aneurysms.  
The hallmark pathologic feature of atherosclerosis is foam-cell formation, 
whereas aneurysms are typified by intense oxidative stress, inflammation, 
matrix degradation, and apoptosis of smooth-muscle cells.” 
 The normal aorta has a heavily elastic media that enables the 
vessel to withstand the demands placed on it by the nature of its location 
in the arterial tree.  The media is delineated from the intima and the 
adventitia by layers of elastin, the internal and external elastic lamina, 
respectively.  Finally, the adventitial layer of the aorta is heavily 
populated by collagen that provides a large proportion of the overall 
resistance to changing hemodynamic factors in the vessel. 
 Although the abdominal aorta, along with other vessels, stiffen and 
enlarge with age, the development of a dilatation greater than 2.5cm in 
the abdominal aorta is considered the beginning of AAA development.  
The progression of the disease from this point is typically characterized 
by degradation of elastin in the vessel media and breakdown of collagen, 
particularly in the adventitia.  This breakdown is exacerbated by factors 
contributing to atherosclerosis, such as inflammation and arterial wall 
remodeling, promoted in all likelihood by hemodynamic factors affecting 
the arterial wall stress.  The wall tissues of AAA produce great amounts 
of inflammatory cytokines, chemokines, and prostaglandins.  This 
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inflammatory response leads to the recruitment of immune cells, 
particularly T-lymphocytes, which stimulate resident macrophages to 
produce MMPs.  MMPs are a group of enzymes, some of which are the 
primary contributors, along with elastase, to the degradation of elastin.  
Included amongst MMPs important to AAA are several collagenases and 
gelatinases, which contribute to the breakdown of Type I and Type IV 
collagen.  This inflammatory degradation of the arterial wall is the 
primary contributing factor to the mechanical changes which occur to 
enable aneurysm formation.  Finally, the balance of collagen and elastin 
production with its degradation must be disrupted in order to generate 
the conditions under which an aneurysm can form.  Smooth muscle cells 
are the principle cells responsible for production of collagen and elastin.  
Whereas in the case of atherosclerosis smooth muscle cells can 
proliferate or maintain their normal density, in AAA the density of these 
cells is often severely reduced.  This is the process by which balance is 
disturbed and AAA progression may continue. (Thompson, Geraghty, & 
Lee, 2002). 
 Hemodynamic factors in the aorta are thought to contribute 
significantly to aneurysm expansion.  As the composition of the aortic 
wall changes, the aorta is allowed to dilate under normal hemodynamic 
stress.  This dilatation has a noticeable effect on the wall stress and 
tension responses of the tissue to the normal blood flow and pressure.  
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In a mechanical model of the aorta, this causes the vessel to transition to 
a morphology that becomes more spherical over time as it expands (Vorp, 
Raghavan, & Webster, 1998).  The infrarenal portion of the aorta is the 
most common location for AAA formation, probably in relation to these 
mechanical findings.  Dilatation can occur at any place along the vessel, 
with other common locations being thoracic or juxtarenal aorta.  One 
possible explanation for the common infrarenal localization of AAA is the 
hemodynamic factors arising from the iliac bifurcation.  The division of 
the aorta at this point, in combination with the typically seen 
atherosclerotic comorbidities, creates a turbulent environment in the 
infrarenal portion of the aorta.  The pressure and flow within the 
infrarenal aorta due to these factors could therefore contribute to 
dilatation and variable aortic morphologies. 
 Typically, a good deal of emphasis has been placed on the diameter 
of the aorta in relation to risk of sac enlargement and rupture.  Despite 
the fact that aortic diameter has shown itself to be an acceptable 
surrogate for risk among patients with AAA, it has also been seen that 
aneurismal morphology plays a role in the progression of AAA (Vorp, 
Raghavan, & Webster, 1998; Shum et al., 2011).  Though the infrarenal 
aneurysm has a mostly spherical shape with a bias towards bulging 
anteriorly, there exists a variety of morphologies, and therefore some 
emphasis has been placed on uncovering how biomechanical analyses 
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can be used to help predict which patients may see a higher risk of 
rupture (Kontopodis et al., 2013; Sonesson, Sandgren, & Länne, 1999). 
 AAA is a multifactorial disease process with many contributing 
factors.  Once a dilatation of the aorta occurs, both molecular and 
hemodynamic factors affect the disease progression towards rupture, the 
natural endpoint for AAA.  Annually, the rate of rupture in aneurysms 
measuring less than 5.5cm diameter is approximately 1%. (United 
Kingdom Small Aneurysm Trial Participants, 2002).  Although this risk is 
low, appropriate management of AAA must be observed at all stages of 
the disease due to the very high mortality rate in the event of rupture. 
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II. Management of AAA 
1. Screening and Surveillance 
 All of the risk factors discussed above play a role in AAA 
development, not only in terms of identifying patients who are at risk but 
also in determining how physicians will surveil the patient once 
dilatation has been discovered.  Several studies have shown that repair 
of small aneurysms is not beneficial in terms of survival, particularly the 
UK Small Aneurysm Trial (Powell, 2007).  Therefore surgery is not 
recommended until the aneurysm reaches the 5.5cm diameter threshold.  
The recommended follow-up regimen varies with the diameter of the 
aneurysm (Table 1).  For high risk patients, surveillance should be 
adjusted particularly among those who smoke and those whose 
aneurysm is growing at an increased rate (Brady, Thompson, Fowkes, 
Greenhalgh, & Powell, 2004).  Given some annual rate of expansion of 
the aorta in patients with AAA, there is a need for considering medical 
treatments along with surveillance before the aneurysm reaches a level 
at which it needs to be repaired. 
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Table 1: Society for Vascular Surgery Guidelines on Screening and 
Surveillance.  These recommendations are based on collective evidence 
from large trials of aneurysm growth and screening protocols.  Some 
recommendations contradict the opinion of the United States Preventive 
Services Task Force.  Diameters given are the maximum external diameter 
of the aorta. 
 
Men Women 
 Not High 
Risk 
Family History 
of AAA or 
History of 
Smoking 
Not High 
Risk 
Family History 
of AAA or 
History of 
Smoking 
Initial 
Screening Age ≥ 65 yrs Age ≥ 55 yrs None Age ≥ 65 yrs 
Diameter < 
2.5cm 
Rescreening 
not 
recommended 
5 year intervals Not 
addressed 
Rescreening    
not 
recommended 
Diameter 
2.6 - 2.9cm 5+ year intervals 
Diameter 
3.0 - 3.4cm 3 year intervals 
Diameter 
3.5 - 4.4cm 12 month intervals 
Diameter 
4.5 - 5.4cm 6 month intervals 
 
 
 
 A study published by the Veteran’s Affairs Cooperative Study 
Group investigators (Lederle et al., 2002) showed that, across a mean 4.9 
years of follow-up, patients with AAA less than 5.5cm showed no 
difference in mortality between surveillance and elective repair.  
Similarly, the UKSAT trial (Powell, 2007) showed that at 12 years, there 
was no statistical difference in mortality between groups of patients 
 14 
undergoing early operative repair (<5.5cm diameter) or ultrasound 
surveillance.  Interestingly, according to the data from this trial, early 
surgical repair was more expensive than ultrasound surveillance in the 
long-term, even when considering that approximately 75% of surveillance 
patients underwent surgical repair during the 12 years of follow-up.  
More recently, the PIVOTAL trial (Ouriel, Clair, Kent, Zarins, & Positive 
Impact of Endovascular Options for treating Aneurysms Early (PIVOTAL) 
Investigators, 2010) showed that, for EVAR, repair of aneurysms between 
4 and 5 cm diameter does no harm.  The reality of this, however, is that 
EVAR is far more expensive than surveillance and still provides no 
benefit to repair at diameters less than 5cm.  The nature of AAA is that it 
will continue to expand and therefore patients with a small sac diameter 
still will require intervention – particular consideration is given to the 
question of the patient’s life expectancy.  The MASS study provided a 
large-scale estimation of the rate of repair among AAA patients.  In the 
group that received aneurysm screening, the rate of elective repair was 
about 45%, which agrees with a smaller study investigating screening 
regimen outcomes (Svensjö, Björck, & Wanhainen, 2013; Thompson et 
al., 2012). 
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2.  Pharmacotherapeutic Strategies 
 Due to the close association between AAA and atherosclerosis, 
HMG-CoA reductase inhibitors have been investigated as a possible 
avenue by which to arrest AAA growth.  Several analyses have shown a 
lower aneurysm growth rate among patients taking statin drugs 
(Schlösser et al., 2008; Sukhija, Aronow, Sandhu, Kakar, & Babu, 2006; 
Takagi et al., 2012), though these findings have seen some disagreement 
in meta-analysis studies (Twine & Williams, 2011).  In spite of the lack of 
any clear link between cholesterol levels and AAA development, statins 
demonstrate a wide range of pleiotropic effects.  In fact, statins can 
reduce protease activity among MMPs implicated in aortic wall dilatation 
(Takagi et al., 2012). 
 In the same avenue as statins, ACE inhibitors have been 
investigated as a possible adjunct in AAA surveillance.  More so than 
statin therapy, findings from analyses of ACE inhibitors have been highly 
variable.  One large review of a Canadian database found that the use of 
ACE inhibitors was correlated with significantly lower rates of aneurysm 
rupture (Hackam, Thiruchelvam, & Redelmeier, 2006).  However, a 
review of data from the UK Small Aneurysm Trial showed that ACE 
inhibitors actually seemed to increase aneurysm growth rates (Sweeting, 
Thompson, Brown, Greenhalgh, & Powell, 2010).  These conflicting 
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findings are enough to call into question the use of ACE inhibitors as 
appropriate therapy for patients under surveillance. 
 Due to the proposed significance of the role of MMPs in the 
development and progression of AAA, and efficacy against the associated 
C. pneumoniae, antibiotics in the tetracycline class have been suggested 
as a potential intervention for AAA.  In a very small pilot study of 
doxycycline for AAA, researchers found that treatment reduced the 
expansion rate of aneurysms during the 6-18 month follow-up period 
(Mosorin et al., 2001).  Another small trial that specifically investigated 
the effect of doxycycline on the proposed inflammatory mechanisms of 
AAA found that drug therapy significantly decreased levels of several 
MMPs in the aortic wall tissue, as well as neutrophil elastase and 
collagenases (Abdul-Hussien et al., 2009).  Despite basic scientific 
evidence and several small scale studies suggesting favorable results of 
this treatment methodology, Dodd and Spence (2011) note that there is a 
distinct lack of larger scale trials on this topic, and that further 
investigation is needed. 
 Apart from pharmacological therapy, a regimen of cardiovascular 
health changes is likely to be effective.  Smoking cessation, as with 
atherosclerosis and other diseases, will benefit the patient and slow 
progression of the aneurysm (Lederle, Nelson, & Joseph, 2003; Mani, 
Wanhainen, Lundkvist, & Lindström, 2011).  Because cardiovascular 
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factors and overall health may affect the outcomes of surgical 
intervention, it is of the utmost importance to ensure that all facets of 
the patient’s health are in optimal condition during the surveillance 
period in the case of the need for surgical repair. 
 
3.  Open Surgical Intervention 
 The typical open operation for an infrarenal AAA is performed 
under general anesthesia and begins with incision to the peritoneum and 
retraction of the bowels.  The affected portion of the aorta is exposed to 
the extent of the renal arteries and the common iliac arteries.  The aorta 
is clamped to interrupt blood flow through the vessel, followed by 
clamping of the iliac arteries.  This isolates the aneurysm and allows 
resection of the affected portion to continue.  An incision is made along 
the length of the aneurysm, exposing the lumen of the vessel in which is 
typically found a thrombus.  After extraction of the thrombotic material, 
the proximal wall of vessel is divided either partially or completely from 
the normal aorta in preparation for graft attachment.  Subsequently, the 
graft is measured and fitted to the patient and is anastomosed 
proximally.  With the distal openings of the graft clamped, the 
anastomosis is checked for leakage by releasing the aortic clamp.  
Subsequently, the distal branches of the graft are anastomosed with the 
iliac arteries and again momentary release of the aortic clamp is used to 
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ensure successful connections.  Careful recovery of normal blood flow 
through the aorta to the limbs is established to complete the grafting 
procedure.  Upon closure, the patient is typically transferred to the ICU 
for one to two days for careful monitoring (Zollinger, Robert M. & Ellison, 
E. Christopher, 2010). 
 Perioperative morbidity among open repair patients has been well 
determined, as the operation has been in use for about half a century.  
The mortality rate of the operation has been found as high as 10%, but 
typically falls in the range of 4-8% (Blankensteijn, Lindenburg, Van der 
Graaf, & Eikelboom, 1998; Dangas et al., 2012; Huber et al., 2001).  
Common morbidities of open repair include cardiac events (such as 
myocardial infarction), pneumonia, renal insufficiency, hemorrhage, and 
colonic ischemia.  The rates of these complications range from 15% for 
all cardiac complications to 1% for colonic ischemia (Chaikof et al., 
2009).  Operative morbidity is exacerbated among certain groups of 
patients.  In particular CAD is one of the primary contributors to 
perioperative, all-cause mortality amongst AAA patients.  Diabetes 
Mellitus has also been suggested as an influential factor in operative 
outcomes (Leurs, Laheij, Buth, & EUROSTAR Collaborators, 2005).  
Long-term follow-up of open repair patients is not mandated and 
therefore is often not well defined in many research studies.  For this 
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reason, the longer term outcomes of open repair are not as clear as for 
the EVAR procedure. 
 Common late complications particular to the open procedure 
include incisional hernias, small bowel obstruction due to adhesion 
formation, and paranastomotic pseudoaneurysm formation (Chaikof et 
al., 2009; Edwards, Teefey, Zierler, & Kohler, 1992; Matsumura, Pearce, 
Cabellon, McCarthy, & Yao, 1999).  Graft infection carries a very high 
mortality rate, though it is a relatively uncommon complication. 
 
4.  Endovascular Aneurysm Repair 
 The endovascular repair procedure for a similar aneurysm is quite 
dissimilar.  Typically, the vascular system is accessed via the femoral 
artery under general anesthesia; local anesthesia can also be used.  A 
stiff guidewire is advanced, in opposition to blood flow, into the thoracic 
aorta.  The stent graft device is contained in a delivery device which is 
advanced over the guidewire and positioned in the abdominal aorta 
under imaging guidance.  The device is deployed just below the renal 
arteries, with the proximal opening of the graft being secured in the wall 
of the normal aorta.  The delivery device continues to be withdrawn to 
the level of the ipsilateral iliac artery, such that the opening of the graft 
providing for the contralateral limb is exposed.  At this point, the 
contralateral femoral artery is accessed in order to deploy the 
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contralateral limb of the graft.  The device for delivering this portion is 
advanced under guidance into the lumen of the main graft.  It is 
deployed in full by securing it within the opening of the main graft at the 
iliac bifurcation and withdrawing the delivery catheter.  Finally, the 
ipsilateral limb of the graft is deployed in full into the iliac artery (Ashley, 
Stanley & American College of Surgeons, 2008; Brunicardi, F. Charles et 
al., 2010). 
 It is required for the endovascular approach that the endograft be 
fixed in place within the aorta.  This disallows migration of the graft 
within the vessel and prevents blood from entering the aneurysm sac.  To 
achieve this, the graft must be sealed along the wall of the vessel at the 
proximal and distal openings, as well as to the wall of the graft itself in 
the case of the seal between the graft’s body and limb.  This fixation has 
been achieved in several ways.  In all grafts the proximal end should be 
sealed to the aortic neck – the region of the normal aorta which extends 
from the renal arteries to the proximal edge of the aneurismal dilatation.  
This requirement can be an obstacle, as most graft instructions for use 
(IFUs) require a neck length of at least 15mm (Schanzer et al., 2011).  
Fixation of the graft is best achieved by mechanical force at the proximal 
and distal necks, though only one of these locations needs to serve as an 
anchor.  The graft is typically constructed in such a way that it expands 
with a radial force sufficient to support the graft and limit migration.  To 
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maximize fixation of the graft, some companies have implemented small 
hooks or barbs, which are inserted into the vessel wall.  The end result is 
that the endograft hangs from the proximal neck or stands on the distal 
branches (Benharash et al., 2007). 
 
4a.  Endovascular Procedural Morbidities 
 Perioperative morbidities of the EVAR procedure are fairly limited 
due to the minimally invasive nature of the procedure.  Across many 
trials comparing open repair and EVAR, the perioperative mortality rate 
is consistently lower than 2% with a very limited number of trials 
reporting anything higher.  The most common morbidities following 
EVAR are wound healing complications and ischemia (Adriaensen, 
Bosch, Halpern, Myriam Hunink, & Gazelle, 2002; Maleux, Koolen, & 
Heye, 2009).  Bowel ischemia occurs in about 1% of patients, while lower 
limb ischemia from thrombosis or kinking of the endograft occurs in up 
to 3% of procedures.  Less commonly, the endograft can be accidentally 
placed in such an orientation that it occludes one or both of the renal 
arteries.  On occasion the surgical wound can be found in the crease of 
the groin - this increases the risk of such complications as infection, 
which occur in up to 5% of patients.  Graft infection, as with open repair, 
presents a major complication of EVAR.  Although the rate of infection is 
low, it is one of the leading risk factors for conversion to open repair and 
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a significant contributor to mortality among EVAR patients (Moulakakis 
et al., 2010; Turney et al., 2013).  Finally, arterial injury at the access 
site can occur in approximately 3% of patients (Mehta et al., 2014).   
 Finally, a major risk of EVAR is contrast nephropathy (Wald et al., 
2006).  Due to the need for imaging in the precise placement of the 
endograft, significant amounts of contrast material are used resulting in 
a not insignificant risk of acute renal failure.  Though only a small 
proportion of patients will require dialysis, this must be considered 
during the decision making process.  CO2 angiography has been 
suggested as an alternative for reducing contrast exposure (Morito et al., 
2012; Tessarek, 2013).  The tradeoff of this technique, however, is 
increased procedural time and increased radiation exposure (Chao et al., 
2007), and therefore must be used with discretion. 
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4b.  Endoleaks and Endoleak Management 
 
Figure 1:  Endoleaks Type I-IV.  Type I endoleak evolves from an 
inappropriate seal of the endograft to the arterial wall.  Type II endoleak is 
caused by retrograde flow through the aneurysm sac.  The Type III 
endoleak shown here is the result of failure to seal two sections of the 
endograft.  Type IV endoleak arises from fluid diffusion through a porous 
graft pressurizing the aneurysm sac.  This figure was taken from 
Greenhalgh, et al. (2008) New England Journal of Medicine.   
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 The goal of the endograft is to completely exclude the affected 
segment of the aorta, with blood flowing freely through the lumen of the 
graft.  The discovery of blood flow into the aneurysm sac is known as an 
endoleak.  The flow of blood within the sac can lead to pressurization of 
the aneurysm and cause continued expansion.  This is the primary 
complication arising from EVAR and it has been estimated that this leads 
to a necessary secondary intervention in 20% of patients (Lederle et al. 
2012; Mehta et al., 2010). 
 Endoleaks are divided into five categories.  Type I endoleaks are 
caused by inadequate fixation of the graft material to the wall of the 
aorta due to a loss of mechanical force or migration of the graft.  This 
constitutes a major failure of the graft as no exclusion of the aneurysm 
has been achieved.  A common useful fix for this type of endoleak is to 
use a balloon to reestablish fixation with the aortic wall (Faries et al., 
2003).  If discovered during the initial graft placement, this can be fixed 
intraoperatively, but if this arises during postoperative follow-up, a 
secondary procedure is required.  There is a further subdivision of Type I 
endoleaks, with Type Ia occurring in the proximal segment of the graft 
and Type Ib occurring distally.  While Type Ia can usually be fixed by 
balloon as described, Type Ib endoleaks are often remedied by extending 
the distal limb of the graft and establishing fixation more distally in the 
vessel. 
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 Type III endoleaks occur when the material of the endograft fails to 
create a competent channel along the aneurysm length.  This is most 
often due to a failure of the seal between the body of the graft and the 
distal limbs of the iliac branches.  Rarely, this type of endoleak can occur 
due to breakdown of the graft material (Abouliatim, Gouicem, Kobeiter, 
Majeski, & Becquemin, 2010; Faccenna, Bresadola, Alunno, & Gattuso, 
2012).  The typical procedure for repairing Type III endoleaks is to place 
a small stent at the location of the graft failure, enabling full exclusion of 
the aneurysm. 
 The direct leakage of blood at physiological pressures into the 
aneurysm sac causes immediate pressurization and essentially negates 
the effect of the intervention.  This leads to an increasing diameter and 
an increasing risk of rupture in these patients (Buth & Laheij, 2000).  
One database review found that among patients with late rupture 
following EVAR, more than 40% were linked with Type I and III endoleaks 
(Schlösser et al., 2009). Both Type I and III endoleaks are serious in 
nature and must be treated in order to maintain the integrity of the 
repair. 
 Type II endoleaks are one of the most common causes of endograft 
complications, observed in up to 30% of patients following elective EVAR 
(Ozdemir et al., 2013; Turney et al., 2013).  They arise from retrograde 
blood flow through small branches of the aorta which remain patent after 
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the endograft implantation.  Common sources of this retrograde flow are 
the lumbar arteries and the inferior mesenteric artery.  It is worth noting 
that there is a requirement for at least two vessels to remain patent as 
the flow of blood within the sac requires both an ingress and an egress. 
 There is a variable prevalence of Type II endoleaks and a 
meaningful rate of spontaneous resolution.  Combined with a low rate of 
secondary interventions for this indication, the management of these 
endoleaks has been less clear (Sheehan et al., 2006).  Type II endoleaks 
are often detected later in the follow-up period and these patients present 
with a significantly increased chance of aneurysm expansion at the five 
year mark (Zhou et al., 2013; Cieri et al., 2013).  However, studies show 
that this aneurysm expansion is equally likely to continue among 
patients who have undergone reintervention and those who have not 
(Cieri et al., 2013; Jouhannet et al., 2014).  The source of the endoleak 
may play a role in the success of secondary interventions.  A 
retrospective review by Gallagher and colleagues (2012) found that the 
source of the Type II endoleak affects the success of reintervention.  
Patients with an inferior mesenteric artery source achieved a 72% 
success rate when undergoing an additional procedure, while patients 
with a lumbar artery source only achieved a 40% success rate. 
 Type IV endoleaks arise from leakage of blood through the graft 
material.  This can be due to increased porosity of the graft, but it is 
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considered to be self-limiting and no treatment is necessary.  Type V 
endoleaks are also known as endotension.  The pressurization of the 
aneurysm in this case is caused by transmission of pressure from the 
lumen of the graft to the wall of the aorta.  The causes of this type of 
endoleak are not well defined, but include leakage of fluids across the 
graft walls, and transmission of pressure through thrombotic material 
within the aneurysm.  Treatments for this type of endoleak must be 
individualized. 
 
4c.  Patient Follow-up 
 In the case of endovascular repair, the common standard of follow-
up care is CT surveillance of the aneurysm at post-operative months 1, 
3, 6, 12 and annually thereafter (Chaikof et al., 2009).  This is a 
significant burden to the patient and the health care system in terms of 
both radiation exposure and cost efficiency.  In comparison, for open 
repair, the recommendation by the Society for Vascular Surgery is follow-
up CT at five year intervals.  The follow-up regimen, particularly among 
EVAR patients, has raised the question of radiation exposure.  The 
lifetime estimated risk of cancer death arising from CT among patients in 
the typical AAA repair age group (50-85 years) is less than 0.2% (Brenner 
& Hall, 2007), however the sheer number of patients undergoing EVAR 
each year means this could affect a significant population. 
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 One approach to the problem of cost and exposure has been to 
limit the follow-up of EVAR patients (Kirkpatrick, Wilson, Williams, & 
Gordon, 2013).  In a single-center review of patient records, it was found 
that among patients with a normal one month CT evaluation, 7.1% of 
patients developed an endoleak.  Of these patients, about 3% required 
reintervention, and these endoleaks were discovered after the 3rd year 
annual CT follow-up.  Furthermore, between groups with a normal and 
abnormal 1 month CT, the group with normal results showed 
significantly less aneurysm expansion.  It may therefore be possible, on a 
case-by-case basis, to safely provide less frequent follow-up to these 
patients (Tomlinson et al., 2007). 
 Another approach that has been heralded as a safe alternative to 
CT has been the use of ultrasound.  It has been shown that color 
Doppler ultrasound shows a strong correlation with CT imaging, but that 
it may be less sensitive and therefore less useful in detecting endoleaks 
(AbuRahma, Welch, Mullins, & Dyer, 2005).  One systematic review 
found that ultrasound sensitivity was as low as 69%, but with a 
specificity that exceeded 90% (Ashoke et al., 2005).  It was also found 
that ultrasound was effective at identifying Type I and III endoleaks as 
opposed to Type II, but this finding was non-significant.  Several more 
recent studies have contradicted these conclusions, showing a great 
efficacy of ultrasound surveillance with contrast material to enhance 
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imaging, including its ability to detect some endoleaks which were 
unavailable on CT imaging (Collins, Boros, & Combs, 2007; Henao et al., 
2006).  Under a paradigm in which ultrasound was used as the primary 
method of follow-up, it was found that ultrasound was safe and effective 
in practice and when modeled against a case series (Chaer et al., 2009).  
Several studies have shown that contrast enhanced ultrasound may be 
an appropriate alternative to CT follow-up, particularly following a 
normal one month CT, and tailored follow-up is appropriate in stable 
patients (Go, Barbato, Rhee, & Makaroun, 2008; Sternbergh III, 
Greenberg, Chuter, & Tonnessen, 2008). 
 Ultrasound follow-up to reduce the cost and radiation exposure of 
CT imaging could be an effective management strategy for EVAR 
patients.  This decision should be made on an individualized basis and 
CT is still the gold standard as there is conflicting evidence about the 
sensitivity of ultrasound to detect endoleaks.  In addition to general 
monitoring for graft infection and cardiovascular corollary events, close 
follow-up including imaging is vital to patient safety. 
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5.   Open Repair vs. Endovascular Repair 
 With the evolving face of AAA surgical interventions, EVAR has 
shown great promise as an intervention as studies have found a 
reduction of perioperative morbidity and mortality.  Furthermore, the 
relative ease of the procedure on the patient’s behalf makes this 
approach appealing and can be appealing to patients for the immediate 
quality of life.  However, while many trials have seen short-term benefits 
to EVAR, follow-up results over time have brought the long-term efficacy 
of EVAR into question.  A relatively high rate of necessary reintervention, 
need for lifetime follow-up, and high costs have made the choice between 
EVAR and open repair a substantial tradeoff.  Moreover, the post-
operative and long-term management of AAA patients is evolving and 
requires further study.  It is important for both patient and provider to 
understand this balance of variables when choosing between these 
procedures. 
 Over the past decade, several major studies have been undertaken 
comparing patient outcomes following open and endovascular repair for 
AAA.  It is widely accepted that perioperative mortality is significantly 
reduced amongst appropriate patients undergoing EVAR as opposed to 
open repair.  As time passes, however, the patient outcomes become less 
definite.  Questions remain regarding how to most appropriately manage 
EVAR patients and what kind of follow-up and reintervention is 
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necessary to maintain the effectiveness of the repair.  Long-term 
outcomes and follow-up data from many of the large clinical trials 
continue to be published, shedding light on how EVAR patients fare over 
time and what problems are common and need to be monitored. 
 
5a.  The DREAM Trial 
 In 1999, the Dutch Randomized Endovascular Aneurysm 
Management (DREAM) trial was undertaken to broadly investigate the 
outcomes of elective AAA surgical management.  Follow-up publications 
from this trial continue to provide important data on patient outcomes 
following elective surgery.  The trial was a smaller one, including 345 
patients in treatment groups.  These participants had aortic dilatations 
of at least 5cm and were appropriate candidates for surgical intervention, 
including a requirement of at least two years life expectancy – in other 
words, participants were low risk patients.  Patients were randomized to 
undergo EVAR by an experienced team (more than five procedures) using 
FDA approved and IDE devices, or conventional open repair (Prinssen, 
Buskens, & Blankensteijn, 2002). 
 The DREAM trial participants first reported data in the year after 
enrollment ended (Prinssen et al., 2004).  Immediate benefits to EVAR 
repair included a lower rate of general anesthesia usage, a shorter 
operative time, lower amount of blood loss, and shorter ICU stays.  The 
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operative data, however, did show a significantly higher rate of iliac 
artery sacrifice in the endovascular repair group.  Post-operatively at 30 
days, patients in the EVAR group showed a lower rate of mortality and a 
lower rate of systemic complications.  The open repair group, expectedly, 
had a significantly lower risk of graft related complications. 
 These results have been supplemented by additional follow-up at 
several times over the years.  Most importantly, the DREAM trial 
participants released two-year outcomes data showing changes in the 
relationship between open and endovascular repair advantages.  At two 
years post-operatively, the mortality rates between both groups had been 
equalized (Blankensteijn et al., 2005).  Furthermore, the complication-
free survival rate was similar between the two groups.  These data 
indicate a decrease in the benefit to EVAR as time passes, though it has 
been noted that the rates of aneurysm-related mortality remained lower 
in the endovascular treatment group.  In other words, a significantly 
greater number of patients who underwent EVAR died during post-
operative follow-up as compared to the open repair group.  In addition, 
open repair proved to be significantly more permanent during the first 
two years of follow-up as the reintervention rate for the EVAR group was 
nearly three times greater than the open repair group (hazard ratio 2.9).  
These data were the first long-term set to be provided during this time 
period and raised questions about the viability of the endovascular 
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approach over time (Bush, Mureebe, Bohannon, & Rutherford, 2008).  
Recently, data from this study revealed that over the long-term there is 
no difference in renal function between the two groups (de Bruin et al., 
2013).  The estimated glomerular filtration rate in both groups declined 
over time, but neither group faired better than the other.  Considering 
the need for lifelong follow-up, particularly for patients undergoing 
EVAR, it is important that renal function is preserved.  While renal 
function declined in both groups, the decline was within ranges found in 
the normal population.  This finding shows that the choice of EVAR as an 
intervention will not affect the quality of follow-up care that is provided. 
 Some additional data were produced by this trial with regards to 
quality of life – a factor which is very important considering the 
population being studied.  The DREAM investigators administered a set 
of questionnaires to patients about their quality of life at intervals of 3 
and 6 weeks, 3, 6, and 12 months post-operatively, as well as 
preoperatively.  An analysis showed that both interventions negatively 
impacted quality of life inside the 3 immediate post-operative weeks, but 
with EVAR patients fairing significantly better.  On all measures EVAR 
patients returned to baseline level by 6 weeks, yet open repair patients 
remained significantly below baseline in some, but not all, measures 
(Prinssen, Buskens, Blankensteijn, & On behalf of the DREAM trial 
participants, 2004).  Overall, this and other studies have shown that it 
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can take up to 6 months for open repair patients to recover their quality 
of life to preoperative levels (Aquino, Jones, Zullo, Missig-Carroll, & 
Makaroun, 2001; Lloyd, Boyle, Bell, & Thompson, 2000).  On a more 
specific measure of quality of life, sexual dysfunction, it was found that 
AAA intervention increased rates of sexual dysfunction significantly, but 
that patients undergoing EVAR were able to recover within 6 weeks while 
open repair patients took about 3 months to recover fully (Prinssen et al., 
2004). 
 These data suggest that EVAR has a distinct benefit to the patient 
in terms of quality of life; however, this is not a sustained and long-term 
benefit.  Furthermore, the surgeon should be aware of this benefit when 
making recommendations to the patient as it could certainly have an 
effect on how the patient approaches the decision to undergo surgical 
intervention. 
 
5b.  EVAR 1 and 2 
 With enrollment beginning in 1999, the UK EndoVascular 
Aneurysm Repair Trials (EVAR 1 and EVAR 2) enrolled participants in 
the UK until 2004.  EVAR 1 was a comparison of endovascular versus 
open repair in patients eligible for either, with aortic dilatations greater 
than 5.5cm.  EVAR 2 included only patients who were deemed unfit for 
open repair, and so compared endovascular repair with surveillance.  
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Both trials followed patients for a primary endpoint of mortality, and 
secondary endpoints which included reintervention rates and graft 
failures.  The initial results of the EVAR 1 trial – the 30-day mortality 
results – indicated similar findings to the DREAM trial with a much 
larger number of patients (1,082), which helped to validate the findings 
of the former study.  Operative mortality was significantly reduced 
among patients receiving endovascular treatment in comparison to open 
repair, but it was found that there was a significantly higher rate of 
secondary intervention among this group (Greenhalgh, 2004).  Through 
four years of follow-up in the EVAR 1 trial, there was a sustained benefit 
for patients undergoing EVAR in terms of aneurysm related mortality, 
but the all-cause mortality rate was equivalent in both groups (EVAR 
trial participants, 2005). 
 Long-term results of the EVAR 1 trial were given over eight years of 
follow-up (The United Kingdom EVAR Trial Investigators, 2010).  It was 
found that across time, the benefit to EVAR in aneurysm related deaths 
was not sustained, and that mortality was equivalent between groups.  
Reintervention rates in the EVAR groups were significantly higher than 
the open repair group, with only about half of patients receiving 
endovascular intervention being free of complications at eight years. 
 In contrast, the EVAR 2 trial, for patients who were ineligible for 
open repair, found that there was a significant benefit to EVAR over eight 
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years of follow-up in terms of aneurysm related mortality (The United 
Kingdom EVAR Trial Investigators, 2010).  However, this benefit did not 
translate to increased overall survival, with the all cause mortality 
converging at eight years.  Comparing results from EVAR 1 and 2, the 
graft complication rates and reintervention rate were similar.  This 
suggests that EVAR is no more of a risk in patients who are unfit for 
open repair than patients who are eligible (Brown et al., 2012). 
 An interesting result from the EVAR trials was that within the first 
five years of follow-up there was no statistical difference between groups 
on measures of cardiac events.  EVAR 1 showed a non-significant 
decrease in cardiovascular events among EVAR patients as opposed to 
open repair, but this did not reach significance (Brown, Thompson, 
Greenhalgh, Powell, & Participants, 2011).  This suggests that, while 
there is a possibility that EVAR could spare some morbidity and 
mortality compared to open repair, this should only be considered in 
patients who are perhaps at higher risk.  In EVAR 2, there was no 
difference between patient groups on measures of cardiovascular 
outcomes (Brown, Greenhalgh, Thompson, Powell, & EVAR Trial 
Participants, 2010).  In this case, these findings suggest that EVAR 
should be safe in the case of a patient who is unfit for open repair, in 
terms of cardiovascular corollaries. 
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5c.  OVER Trial 
 The Open Versus Endovascular Repair Veteran’s Affairs 
Cooperative Study Group trial (OVER) was a prospective randomized trial 
conducted within the Veteran’s Affairs system comparing open and 
endovascular repair for AAA.  This was similar to the DREAM and EVAR 
1 trials, however patient criteria were modified (Lederle et al., 2009).  
Selection criteria included aneurysms greater than 5cm in diameter, as 
well as aneurysms greater than 4.5cm in diameter with a recent history 
of rapid enlargement.  In agreement with previous studies, the first 
report from the OVER trial found a significantly reduced mortality in the 
short-term, but the primary outcome of this study was the long-term 
mortality.  Operative and aneurysm related morbidity was similar 
between both groups, however the endovascular repair group did show a 
significantly increased rate of claudication. 
 At the two-year mark of the study, data supported the assertion 
that EVAR resulted in a sustained benefit in operative mortality.  Of note, 
the data produced by the OVER trial differed from both the EVAR 1 and 
DREAM trials.  Thirty-day mortality was lower among patients in the 
OVER trial than either of the others in both EVAR and open repair 
groups (Lederle et al., 2009).  When the long-term results of this trial 
were released it was seen that the initial sustained benefit to EVAR was 
eliminated over the eight years of study follow-up (Lederle et al., 2012). 
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 Subgroup analyses of patients showed several significant 
differences.  Of primary note amongst these was the effect of age.  The 
presumption of the authors was that results would corroborate the 
supposition that EVAR would result in better outcomes for the elderly 
who would be at greater surgical risk when undergoing the major open 
repair procedure.  However, the long-term results of this study showed a 
significant difference between hazard ratios for those on either side of 70 
years old, with greater EVAR survival amongst younger patients.  
Additionally, the date of patient randomization apparently played a role, 
with a later enrollment showing a hazard preference for EVAR.  This 
might suggest that as EVAR became more widely used and as skill and 
technology improved, the endovascular procedures became more safe 
and successful.  Finally, within the OVER trial, there was a trend 
towards more frequent secondary interventions among EVAR patients, 
but this difference was statistically insignificant.  This differs from what 
was found in both the DREAM and EVAR 1 trials (Blankensteijn et al., 
2005; The United Kingdom EVAR Trial Investigators, 2010), which 
showed endovascular repairs to more often require a secondary 
intervention.  Logically, this is acceptable, but the authors of the OVER 
trial note that neither of the previous trials involved close follow-up of 
open repair patients for operative morbidity whereas their trial did 
(Lederle et al., 2012). 
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 Prior to the publication of these more recent trials, some of the 
published evidence had shown that EVAR might have been unfavorable 
in comparison to traditional open repair, and this had prompted some 
experts to decry the use of endovascular technologies (Collin & Murie, 
2001).  But EVAR is again gaining favor as an elective approach 
(Rutherford, 2006), and results of the OVER trial “suggest that 
endovascular repair continues to improve and is now an acceptable 
alternative to open repair” (Lederle et al., 2012).  Still, these major trials 
and others have demonstrated and validated certain issues with 
endovascular repair – namely the need for subsequent interventions and 
lifelong follow-up. 
 
5d.  Epidemiological Considerations 
 Several factors have been identified as possible contributors to 
failure of both open and endovascular aneurysm surgeries.  
Comorbidities such as metabolic syndrome and CAD have been shown to 
be associated with increased risk following endovascular repair, while 
extensive atherosclerosis and renal insufficiency have been associated 
with failures of open aneurysm repair (Coscas et al., 2010; Hall et al., 
2013).  Aside from pathophysiological factors such as these, 
epidemiological factors have also been shown to have an important 
association with elective repair. 
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 Surgery is a major undertaking at any point in life, and the 
magnitude only increases with age. With an annual risk of rupture for 
aneurysms of 5 cm being approximately 5%, repair may be unnecessary 
for very elderly or infirm patients (Mohler, Emile R., 2014).  Members of 
the Vascular Study Group of New England retrospectively analyzed over 
2,000 elective repairs of infrarenal AAA with an eye to life expectancy.  
They point out that the 5.5cm threshold for intervention “assumes that 
the annual risk of rupture exceeds the operative mortality risk and that the 
patient will otherwise survive long enough to overcome the up-front risk of 
surgical treatment” (De Martino et al., 2013).  Patients were included in 
the analysis if they underwent elective AAA repair for aneurysms between 
5.5 and 6.5cm diameter located in the infrarenal region of the aorta.  
Compared with patients treated by EVAR, the proportion (30%) of 
patients undergoing open repair were younger and had less 
cardiovascular risk factors for surgery – with the exception of smoking 
history, which was more prevalent among patients who underwent an 
open repair procedure.  Overall mortality data was consistent with 
findings from the previous major trials comparing open and endovascular 
repair.  For analysis, patients were stratified by risk based on long term 
mortality profile.  It was found that there is a significantly different five 
year survival among patients in each of these risk groups, with major 
contributions to increased mortality coming from recent myocardial 
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infarction, increasing age, COPD, and renal insufficiency.  The authors 
suggest that survival among patients with several comorbidities may be 
less than 50% at the five year interval.  This should be taken into strong 
consideration when deciding whether it is appropriate to treat AAA 
patients by surgical means, especially given that the patient’s age may be 
an independent factor in determining the long term outcome of the 
procedure (Cadili, Turnbull, Hervas-Malo, Ghosh, & Chyczij, 2012). 
 In the long-term, open repair and EVAR have been seen to be 
equivalent in terms of mortality.  Therefore open repair in patients with 
extended life expectancies can reduce the cost and burden of follow-up 
associated with EVAR and reduce the risk of secondary intervention – 
including eliminating the potential need for conversion to open repair, 
which is approximately 1%.  In contrast, patients with reduced life 
expectancies may enjoy some benefit from EVAR while avoiding the risk 
of open surgery and the burden of reinterventions and follow-up in the 
extended term.  
 As much as there is a gender difference in AAA presentation, it 
remains unclear if there is a gender difference in repair.  Several studies 
have presented conflicting information about mortality with respect to 
gender.  Egorova and colleagues (2011) found that women experienced a 
higher mortality rate from elective repair despite lower rates of 
comorbidities.  In contrast, Lo and colleagues (2013) found that while 
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women experience a higher mortality rate following open repair, there is 
no difference in EVAR mortality.  This finding is disputed by another 
study showing a significant increased EVAR mortality among women 
(Mehta et al., 2012).  Though mortality outcomes are conflicting and 
unclear, studies of gender differences in elective repair agree that there is 
a significantly higher rate of complication among women as compared to 
men, especially among women undergoing EVAR (Egorova et al., 2011; 
Grootenboer, Myriam Hunink, Hendriks, van Sambeek, & Buth, 2013; Lo 
et al., 2013; Mehta et al., 2012).  These differences have been primarily 
attributed to anatomical differences in women, which could be a source 
of bias in evaluating the literature on gender differences in AAA repair, 
including conflicting findings (Dubois, Novick, Harris, DeRose, & Forbes, 
2013).   
 
5e.  Economic Impact 
 The cost burden of aneurysm surgery is significant, as can be seen 
from data in the several major randomized clinical trials comparing open 
and endovascular repair.  In the DREAM trial, investigators found that 
the average cost of the open repair procedure was about $18,000 while 
the cost of EVAR averaged over $25,000 (Prinssen et al., 2007).  In their 
analysis of cost-effectiveness, investigators concluded that open repair is 
most likely the preferred method of treatment in terms of the economic 
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impact of one additional quality-of-life-year gained due to the excessive 
cost of EVAR.  The OVER trial also analyzed the cost of intervention.  
Their data on operational cost was similar to that in the DREAM trial, 
but investigators went a step further to look at the total incurred costs of 
the operations.  It was found that the mean cost of open repair was non-
significantly higher than EVAR, and the median cost was equivalent 
(Stroupe et al., 2012).  Costs limited to the operation itself remained 
significantly higher in the EVAR group opposed to the open repair group.  
A possible explanation for the disagreement between these trials cited by 
the authors is the timing of the studies (Lederle & Stroupe, 2012).  
Hospital costs increased significantly between the beginning of DREAM 
trial enrollment and the end of OVER trial enrollment, with associated 
hospital costs accounting for the majority of increased costs in the open 
repair group. 
 The EVAR 2 trial provides another perspective on the issue of costs 
in endovascular repair due to the exclusion of open repair due to 
ineligibility.  Although EVAR provided a significant benefit to these 
patients in terms of aneurysm-related survival, there was no translation 
of this benefit to an overall increased survival (The United Kingdom 
EVAR Trial Investigators, 2010).  The associated costs in the treatment 
group exceeded $22,000 while cost in the non-treatment group was less 
than $7,000 with a net result of equivalent mortality.  Interestingly, the 
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cost of endovascular repair does not appear to have significantly affected 
the choice to perform this procedure among either patients or hospitals, 
with EVAR rates rising over the past decade.  As cost-effectiveness 
continues to be an important factor in healthcare decision-making, 
understanding the costs of EVAR from a provider’s perspective is 
important. Stone et al., (2014) studied the financial implications of EVAR 
in a single-center experience.  Because the vast majority of AAA patients 
are enrolled in the Medicare program, researchers used the Centers for 
Medicare and Medicaid Services remuneration levels as a benchmark, 
and found that the net hospital cost exceeded revenues by over $4,000 
per EVAR procedure.  On average, 52% of the operative costs were 
accounted for by the endograft.  Most notably, as reported by the group, 
the data places this institution in the lowest quartile of costs as 
compared to other comparable academic medical centers. 
 The high cost of EVAR devices puts the practice of endovascular 
repair at high risk in the future.  As political focus in the United States 
continues to shift towards fiscal restraint, the likelihood that hospitals 
will continue to perform this procedure at a loss is declining.  With the 
endograft market growing to almost $2,000,000,000 in revenue in 2012, 
the need for lower cost devices may drive future development on the 
technology and manufacturing side (Research and Markets, 2013). 
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Discussion and Conclusion 
 For much of the 20th century, open repair was the only option for 
patients with AAA.  The advent of endovascular repair provided a novel 
approach to aneurysm repair and expanded patient options.  In 
comparison to open repair, EVAR has a perioperative benefit in terms of 
mortality.  Recent evidence even suggests a benefit to extending this 
method to patients who are not eligible to undergo open repair.  However, 
EVAR also carries risk in the form of a high reintervention rate and a 
lifelong need for rigorous follow-up, dampening the enthusiasm 
generated by the availability of a novel alternative. 
 Despite any concerns, EVAR has proven to be a significant 
advance in the care of patients with infrarenal AAA.  Future 
developments will focus on reductions in the need for reintervention, and 
the consequent reduction in follow-up costs.  New devices are already 
being developed as technology advances rapidly.  For example, the Nellix 
system from Endologix (ELGX: Irvine, CA) aims to eliminate Type II 
endoleaks by filling the aneurysm sac, and is currently enrolling patients 
in its first clinical trial.  In the short term, the development of safer and 
more sensitive imaging technologies may become applicable to AAA 
surveillance and follow-up.  Modalities such as CO2 angiography, 
contrast enhanced ultrasound, low cost MRI, and low power CT will likely 
impact the way endovascular patients are monitored. 
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 Over the extended term, open repair and EVAR are equivalent in 
efficacy.  The conundrum arises in the cost of care and the accumulation 
of risk.  Current changes in the healthcare system of the United States 
could dictate how these surgeries are approached in the future.  Open 
repair is significantly less costly in comparison to EVAR and the EVAR 
procedure requires a shorter hospital stay.  If EVAR is rebranded as an 
outpatient procedure, and reimbursement rates for the surgery decline, 
the endovascular approach could be all but obviated with the exception 
of patients who can pay out of pocket or who are ineligible for open 
repair.   
 Management of AAA is complex and expensive, and no definitive 
stratification exists to guide physicians on how to treat such patients.  
With the advent of EVAR, a novel approach is now available.  In spite of 
doubts about the efficacy of this method, endovascular management of 
AAA patients has opened a new avenue of intervention for patients and 
broadened the population to whom treatment is available.  Therefore 
patient preferences and physician’s judgement will, for now, remain the 
guiding principles of AAA management. 
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